Citations

Clear

813 citation(s) found for "He, Helen".

Infants Admitted to US Intensive Care Units for RSV Infection During the 2022 Seasonal Peak
Halasa, Natasha , Zambrano, Laura D. , Stewart, Laura S , Newhams, Margaret M. , Levy, Emily R. , Carroll, Christopher L. , Fitzgerald, Julie C. , Bline, Katherine , Cullimore, Melissa L. , Loftis, Laura L. , Jeyapalan, Asumthia , Schwarz, Adam J. , Zinter, Matt S. , Irby, Katherine , Kuebler, Joseph D. , Babbitt, Christopher , Gaspers, Mary Glas , Nofziger, Ryan A. , Kong, Michele , Coates, Bria M. , Schuster, Jennifer E. , Gertz, Shira J. , Mack, Elizabeth H. , White, Benjamin R. , Harvey, Helen , Butler, Andrew , Bradford, Tamara T. , Rowan, Courtney M. , Staat, Mary Allen , Aguiar, Cassyanne L. , Randolph, Adrienne G. , Campbell, Angela P. , Investigators, RSV-PIC, Tomcany, Merry, Price, Heather E. , Sanders, Ronald C., Dixon, Lexie, Kücükak, Suden, McNamara, Elizabeth R, Chen, Sabrina R., Listerud, Eve, Vargas-Shiraishi, Ofelia, Oberle, Betty, Zorensky, Frances, Mansour, Rachel, Jumarang, Jaycee , Johnston, Marla , Bush, Jenny L., Dickey, Shawn, Sullivan, Melissa, Kietzman, Abigail , Colston, Candice , Murdock, Meghan, Kelley, Heather M., Wright-Sexton, Laura, Martin, Maygan, Malloch, Lacy , Patterson, Kayla, Sanders, Cameron , Rohlfs, Chelsea , Rice, Marilyn, Howard, Miranda, Murphy, M. Gail, Soma, Vijaya L, Job, Megan , Mennie, Colleen, Simkhada, Kamala, Drapeau, Noelle M., Hayek, Haya , Maranto, Molly, Waters, Aubrie, Flowers, Maggie, Havlin, Kevin , Furlong-Dillard, Jamie , Porter, Melissa , Nason, Jennifer, Ray, Madison, Gossett, Kristen, Crandall, Hillary , Heller, Evan G, Foley, Jennifer, Rasal, Rajashri, Marlow, Christine, Senthil, Anurithi, Myers, Kimberly, Tudor, Betsy, Garcia, Nereyda, Treister, Natalie, Sun, Kathleen, Villarreal-Chico, Denise, Kainaroi, Sophia, Levy, Emily R , Randolph, Adrienne G , Kong, Michele , Staat, Mary A , Gertz, Shira J , Bline, Katherine E , Amarin, Justin Z. , Shein, Steven L. , Michaels, Marian G , Montgomery, Vicki , Pannaraj, Pia S. , Cvijanovich, Natalie Z , Maddux, Aline B. , Bembea, Melania M. , Zerr, Danielle M. , Hobbs, Charlotte V. , Dapul, Heda , Wellnitz, Kari , Hymes, Saul , Investigators, RSV-PIC, Michelson, Kelly Nicole , Typpo, Katri , Harwayne‐Gidansky, Ilana , Bush, Jenny, Hill, Shannon, Kelley, Heather, Martin, Lora , Rice, Marilyn, Howard, Miranda, Murphy, Makayla, Ratner, Adam J. , Behl, Supriya , Betters, Kristina Ann , Maranto, Molly , Nason, Jennifer, Marlow, Christine, Myers, Kimberly, Adler, Amanda , Garcia, Nereyda, McQuillen, Patrick S. , Williams, John V.

Mayo Clinic

JAMA Network Open | August 15, 2023 | Volume: 6 | Issue: 8 | Pages: e2328950

10.1001/jamanetworkopen.2023.28950 | PMID 37581884 Get It

ImportanceRespiratory syncytial virus (RSV) is the leading cause of lower respiratory tract infections (LRTIs) and infant hospitalization worldwide.ObjectiveTo evaluate the characteristics and outcomes of RSV-related critical illness in US infants during peak 2022 RSV transmission.Design, Setting, and ParticipantsThis cross-sectional study used a public health prospective surveillance registry in 39 pediatric hospitals across 27 US states. Participants were infants admitted for 24 or more hours between October 17 and December 16, 2022, to a unit providing intensive care due to laboratory-confirmed RSV infection.ExposureRespiratory syncytial virus.Main Outcomes and MeasuresData were captured on demographics, clinical characteristics, signs and symptoms, laboratory values, severity measures, and clinical outcomes, including receipt of noninvasive respiratory support, invasive mechanical ventilation, vasopressors or extracorporeal membrane oxygenation, and death. Mixed-effects multivariable log-binomial regression models were used to assess associations between intubation status and demographic factors, gestational age, and underlying conditions, including hospital as a random effect to account for between-site heterogeneity.ResultsThe first 15 to 20 consecutive eligible infants from each site were included for a target sample size of 600. Among the 600 infants, the median (IQR) age was 2.6 (1.4-6.0) months; 361 (60.2%) were male, 169 (28.9%) were born prematurely, and 487 (81.2%) had no underlying medical conditions. Primary reasons for admission included LRTI (594 infants [99.0%]) and apnea or bradycardia (77 infants [12.8%]). Overall, 143 infants (23.8%) received invasive mechanical ventilation (median [IQR], 6.0 [4.0-10.0] days). The highest level of respiratory support for nonintubated infants was high-flow nasal cannula (243 infants [40.5%]), followed by bilevel positive airway pressure (150 infants [25.0%]) and continuous positive airway pressure (52 infants [8.7%]). Infants younger than 3 months, those born prematurely (gestational age <37 weeks), or those publicly insured were at higher risk for intubation. Four infants (0.7%) received extracorporeal membrane oxygenation, and 2 died. The median (IQR) length of hospitalization for survivors was 5 (4-10) days.Conclusions and RelevanceIn this cross-sectional study, most US infants who required intensive care for RSV LRTIs were young, healthy, and born at term. These findings highlight the need for RSV preventive interventions targeting all infants to reduce the burden of severe RSV illness.
The Cholangiocarcinoma in the Young (CITY) Study: Tumor Biology, Treatment Patterns, and Survival Outcomes in Adolescent Young Adults With Cholangiocarcinoma
Pappas, Leontios , Baiev, Islam , Reyes, Stephanie , Bocobo, Andrea Grace, Jain, Apurva , Spencer, Kristen , Rahma, Osama E. , Maurer, Jordan R., Stanton, Jen, DeLeon, Thomas, Roth, Marc, Zhu, Andrew X. , Boyhen, Kylie, VanCott, Christine, Roberts, Lewis R. , Lindsey, Stacie , Lennerz, Jochen K. , Iafrate, A. John , Goff, Laura W. , Mody, Kabir , Shroff, Rachna T. , Javle, Milind , Kelley, Robin Katie, Rahma, Osama E , Zhang, Karen , De Armas, Anaemy Danner , DeLeon, Thomas T, Roth, Marc , Peters, Mary Linton B , Zhu, Andrew X , Roberts, Lewis R , Lindsey, Stacie , Lennerz, Jochen , Goff, Laura Williams , Mody, Kabir , Borad, Mitesh J , Javle, Milind M , Kelley, R Katie , Goyal, Lipika , Spencer, Kristen , Pappas, Leontios , Le, Tri Minh , Stanton, Jennifer R., Patel, Tushar , Horick, Nora , Borad, Mitesh J. , Kelley, Robin Kate , Goyal, Lipika

Mayo Clinic

JCO Precision Oncology | August 10, 2023 | Volume: No volume available | Issue: 7 | Pages: No page available

10.1200/po.22.00594 | PMID 37561981 Get It

PURPOSE Increased awareness of the distinct tumor biology for adolescents and young adults (AYAs) with cancer has led to improvement in outcomes for this population. However, in cholangiocarcinoma (CCA), a paucity of data exist on the AYA population. To our knowledge, we present the largest study to date on AYA disease biology, treatment patterns, and survival outcomes in CCA. METHODS A multi-institutional cohort of patients with CCA diagnosed with intrahepatic cholangiocarcinoma (ICC) or extrahepatic cholangiocarcinoma (ECC) was used for analysis. Retrospective chart review was conducted on patients who were 50 years old and younger (young; n = 124) and older than 50 years (older; n = 723). RESULTS Among 1,039 patients screened, 847 patients met eligibility (72% ICC, 28% ECC). Young patients had a larger median tumor size at resection compared with older patients (4.2 v 3.6 cm; P = .048), more commonly had N1 disease (65% v 43%; P = .040), and were more likely to receive adjuvant therapy (odds ratio, 4.0; 95% CI, 1.64 to 9.74). Tumors of young patients were more likely to harbor an FGFR2 fusion, BRAF mutation, or ATM mutation ( P < .05 for each). Young patients were more likely to receive palliative systemic therapy (96% v 69%; P < .001), targeted therapy (23% v 8%; P < .001), and treatment on a clinical trial (31% v 19%; P = .004). Among patients who presented with advanced disease, young patients had a higher median overall survival compared with their older counterparts (17.7 v 13.5 months; 95% CI, 12.6 to 22.6 v 11.4 to 14.8; P = .049). CONCLUSION Young patients with CCA had more advanced disease at resection, more commonly received both adjuvant and palliative therapies, and demonstrated improved survival compared with older patients. Given the low clinical trial enrollment and poor outcomes among some AYA cancer populations, data to the contrary in CCA are highly encouraging.
S202: CARTITUDE-1 FINAL RESULTS: PHASE 1B/2 STUDY OF CILTACABTAGENE AUTOLEUCEL IN HEAVILY PRETREATED PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA
Munshi, Nikhil C. , Martin, Tom, Deol, Abhinav , Htut, Myo , O’Donnell, Elizabeth , Jackson, Carolyn C. , Yeh, Tzu‐Min, Banerjee, Arnob , Zudaire, Enrique, delCorral, Christopher, Pacaud, Lida , Usmani, Saad Z. , Berdeja, Jesús G. , Jakubowiak, Andrzej , Agha, Mounzer , Cohen, Adam D. , Lesokhin, Alexander M. , Lin, Yi , Madduri, Deepu , Jagannath, Sundar

Mayo Clinic

HemaSphere | August 8, 2023 | Volume: 7 | Issue: S3 | Pages: e6102468

10.1097/01.hs9.0000967720.61024.68 Get It

S117: CHEMOTHERAPY-FREE TREATMENT WITH INOTUZUMAB OZOGAMICIN AND BLINATUMOMAB FOR OLDER ADULTS WITH NEWLY-DIAGNOSED, PH-NEGATIVE, CD22-POSITIVE, B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA: ALLIANCE A041703
Wieduwilt, Matthew J. , Yin, Jun , Kour, Oudom, Teske, Rebecca, Byrd, Ken, Doucette, Kimberly, Mangan, James K. , Jamieson, Katarzyna , Dinner, Shira, Bseiso, Ali W., Litzow, Mark R. , Stone, Richard M. , Stock, Wendy , Byrd, Ken, Masters, Gregory A. , Mims, Alice S , Uy, Geoffrey L. , Erba, Harry Paul

Mayo Clinic

HemaSphere | August 8, 2023 | Volume: 7 | Issue: S3 | Pages: e08838b7

10.1097/01.hs9.0000967380.08838.b7 Get It

NCCN Guidelines® Insights: Survivorship, Version 1.2023
Sanft, Tara , Ansbaugh, Shannon, Ballinger, T.J., Demark‐Wahnefried, Wendy , Dickinson, Kristin , Fairman, Nathan, Felciano, Josephine, Flores, Tessa , Gabel, Nicolette , Goldman, Mindy, Henry, N. Lynn , Hill‐Kayser, Christine E. , Koura, Divya, Lee, Kimberly , McDonough, Allison L. , Melisko, Michelle , Mooney, Kathi , Moryl, Natalie , Neuman, Heather B. , Patel, Chirayu G. , Peterson, Lindsay L. , Porpiglia, Andrea S., Rodriguez, Maria Alma , Schapira, Lidia , Smith, Sophia K. , Zee, Phyllis C. , McMillian, Nicole R., Freedman-Cass, Deborah A., Tevaarwerk, Amyé , Henry, N Lynn , Demark-Wahnefried, Wendy , Day, Andrew T. , Armenian, Saro H. , Baker, Kevin Scott , Friedman, Debra L. , Hudson, Melissa M. , Moore, Halle C. F. , O’Connor, Tracey L. , Overholser, Linda , Paskett, Electra D. , Pirl, William F. , Schwartz, Anna L. , Yang, Eric H.

Mayo Clinic

Journal of the National Comprehensive Cancer Network | August 7, 2023 | Volume: 21 | Issue: 8 | Pages: 792-803

10.6004/jnccn.2023.0041 | PMID 37549906 Get It

The NCCN Guidelines for Survivorship are intended to help healthcare professionals address the complex and varied needs of cancer survivors. The NCCN Guidelines provide screening, evaluation, and treatment recommendations for psychosocial and physical problems resulting from adult-onset cancer and its treatment; recommendations to help promote healthy behaviors and immunizations in survivors; and a framework for care coordination. These NCCN Guidelines Insights summarize recent guideline updates and panel discussions pertaining to sleep disorders, fatigue, and cognitive function in cancer survivors.
Adolescent and Young Adult (AYA) Oncology, Version 2.2024, NCCN Clinical Practice Guidelines in Oncology
Pappo, Alberto S. , Acquazzino, Melissa , Barnett, Marie , Casey, Robert, Choo, Sun , Dinner, Shira, Fair, Douglas , Federman, Noah , Folbrecht, Jeanelle , Gandhi, Shipra , Germann, Julie N. , Goldsby, Robert E. , Hayashi, Robert J. , Huang, Mary , Jacobs, Linda A. , Lee‐Miller, Cathy , Link, Michael P., Lustberg, Maryam B. , Malogolowkin, Marcio H., Oeffinger, Kevin C. , Pratilas, Christine A. , Mehren, Margaret von , Yeager, Nicholas D. , Hang, Lisa, von Mehren, Margaret , Lustberg, Maryam , Bhatia, Smita , Allen‐Rhoades, Wendy , Borinstein, Scott C. , Chugh, Rashmi , Ermoian, Ralph P. , Huang, Alex Yee-Chen , Livingston, J. Andrew , Reed, Damon R. , Skiles, Jodi L. , Montgomery, Sarah E.

Mayo Clinic

Journal of the National Comprehensive Cancer Network | August 7, 2023 | Volume: 21 | Issue: 8 | Pages: 851-880

10.6004/jnccn.2023.0040 | PMID 37549914 Get It

This selection from the NCCN Guidelines for Adolescent and Young Adult (AYA) Oncology focuses on considerations for the comprehensive care of AYA patients with cancer. Compared with older adults with cancer, AYA patients have unique needs regarding treatment, fertility counseling, psychosocial and behavioral issues, and supportive care services. The complete version of the NCCN Guidelines for Adolescent and Young Adult (AYA) Oncology addresses additional aspects of caring for AYA patients, including risk factors, screening, diagnosis, and survivorship.
IDH1 /2 inhibitor monotherapy in blast‐phase myeloproliferative neoplasms: A multicentre experience
Gangat, Naseema , Ajufo, Helen, Abdelmagid, Maymona, Karrar, Omer , Badar, Talha , Foran, James M. , Palmer, Jeanne , Mangaonkar, Abhishek A. , Rampal, Raajit K. , Tefferi, Ayalew , Badar, Talha , Foran, James M , Alkhateeb, Hassan B , Mangaonkar, Abhishek A. , Kuykendall, Andrew , Tefferi, Ayalew , McCullough, Kristen , Alkhateeb, Hassan B.

Mayo Clinic

British Journal of Haematology | August 4, 2023 | Volume: 203 | Issue: 3 | Pages: No page available

10.1111/bjh.19027 | PMID 37537750 Get It

RNA Sequencing for Solid Tumor Fusion Gene Detection: Proficiency Testing Practice and Performance Comparison
Bridge, Julia A. , Halling, Kevin C. , Moncur, Joel T., Souers, Rhona J., Fernandes, Helen , Roy, Angshumoy , Surrey, Lea F. , Tafe, Laura J. , Vasalos, Patricia, López‐Terrada, Dolores , Hameed, Meera

Mayo Clinic

Archives of Pathology & Laboratory Medicine | August 3, 2023 | Volume: 148 | Issue: 5 | Pages: 538-544

10.5858/arpa.2023-0047-cp | PMID 37535666 Get It

Context Next-generation sequencing–based approaches using RNA have increasingly been used by clinical laboratories for the detection of fusion genes, intragenic rearrangements, and exon-skipping events. Correspondingly, the College of American Pathologists (CAP) has advanced RNA sequencing proficiency testing (PT) to ensure optimal performance of these assays. Objective To report on laboratory performance and practices of RNA sequencing for the detection of fusion genes, intragenic rearrangements, and exon-skipping events using CAP PT data from 8 mailings (2018-A through 2021-B). Design CAP PT RNA sequencing program results from 153 laboratories across 24 proficiency test specimens, interrogating 22 distinct engineered fusion transcripts, were analyzed for correct identification of the fusion event, associated performance variables, and laboratory practices. Results Overall, the 4-year program detection rate (sensitivity) was 95.5% (1486 of 1556 results). False-negative rates were 3.6% (53 of 1463) and 18.3% (17 of 93) for fusion gene and intragenic rearrangement/exon-skipping events, respectively. Only 19 false-positive results were reported among the 8 PT mailings, and most were likely the result of preanalytical or postanalytical errors. There were no practice characteristics (eg, instrumentation, sequencing method) significantly associated with the fusion detection results. Conclusions These data reveal a high overall sensitivity and specificity for fusion gene detection by participating laboratories using clinical RNA sequencing. Performance was comparable across all laboratories, regardless of methodology. The fraction of false-negative results for intragenic rearrangement/exon-skipping events was greater than that for the chimeric fusion genes. False-negative results could not be attributed to any specific practice characteristics.
The New NCI Precision Medicine Trials
Harris, Lyndsay N. , Blanke, Charles D. , Erba, Harry P. , Ford, James M. , Gray, Robert J. , LeBlanc, Michael , Hu‐Lieskovan, Siwen , Litzow, Mark R. , Luger, Selina M. , Meric‐Bernstam, Funda , O’Dwyer, Peter J. , Politi, Katerina , Shepherd, Lois E. , Allegra, Carmen J. , Korde, Larissa A. , Little, Richard F. , Moscow, Jeffrey A. , Thurin, Magdalena , Doroshow, James H. , LeBlanc, Michael L , Othus, Megan , Politi, Katerina , Shepherd, LE , Allegra, Carmen J , Chen, Helen X , Ivy, S. Percy , Korde, Larissa A , Little, Richard F , McShane, Lisa M. , Moscow, Jeffrey A , Patton, David R , Thurin, Magdalena , Yee, Laura M , Doroshow, James H , Erba, Harry Paul , Meric-Bernstam, Funda , Gray, Robert J , Patton, David R.

Mayo Clinic

Clinical Cancer Research | August 2, 2023 | Volume: 29 | Issue: 23 | Pages: 4728-4732

10.1158/1078-0432.ccr-23-0917 | PMID 37531248 Get It

Abstract Basket, umbrella, and platform trial designs (master protocols) have emerged over the last decade to study precision medicine approaches in oncology. First-generation trials like NCI-MATCH (Molecular Analysis for Therapy Choice) have proven the principle that studying targeted therapies on a large scale is feasible both from the laboratory and clinical perspectives. However, single-agent targeted therapies have shown limited ability to control metastatic disease, despite careful matching of drug to target. As such, newer approaches employing combinations of targeted therapy, or targeted therapy with standard therapies, need to be considered. The NCI has recently embarked on three second-generation precision medicine trials to address this need: ComboMATCH, iMATCH, and myeloMATCH. The design of these trials and necessary infrastructure are discussed in the following perspective.
A novel rapamycin cream formulation improves facial angiofibromas associated with tuberous sclerosis complex: a double-blind randomized placebo-controlled trial
Aitken, Phillip , Stanescu, Ioana , Boddington, Laura , Mahon, Caroline , Fogarasi, András , Liao, Yi‐Hua , Ivars, Marta , Trauner, Doris A. , DeRoos, Steven T., Nikolić, Miloš , Balážová, Patrícia , Price, Harper , Riney, Kate , Tollefson, Megha M. , Bauer, Derek, Pinková, Blanka, Atkinson, Hartley C., Moreno-Artero, Ester , Jancic, Jasna , Nikolic, Milos , Price, Harper N , Hadzsiev, Kinga , Stapleton, Stacie L. , Bauer, Derek

Mayo Clinic

British Journal of Dermatology | July 17, 2023 | Volume: 189 | Issue: 5 | Pages: 520-530

10.1093/bjd/ljad243 | PMID 37463422 Get It

Abstract Background Facial angiofibromas (FAs) are a major feature of tuberous sclerosis complex (TSC). Topical rapamycin can successfully treat FAs. A new stabilized cream formulation that protects rapamycin from oxidation has been developed in 0.5% and 1% concentrations. Objectives To assess the efficacy and safety of a novel, stabilized topical rapamycin cream formulation. Methods This multicentre double-blind randomized placebo-controlled dose–response phase II/III study with a parallel design included participants aged 6–65 years with FAs of mild or moderate severity according to the Investigator’s Global Assessment (IGA) scale. Participants were randomized to one of three treatment arms: topical rapamycin 0.5%, topical rapamycin 1% or placebo. Treatment was applied once daily for 26 weeks. Safety and efficacy measures were assessed at days 14, 56, 98, 140 and 182. The primary endpoint was the percentage of participants achieving IGA scores of ‘clear’ or ‘almost clear’ after 26 weeks of treatment. Secondary measures included Facial Angiofibroma Severity Index (FASI) and participant- and clinician-reported percentage-based improvement. Safety measures included the incidence of treatment-emergent adverse events and blood rapamycin concentration changes over time. Results Participants (n = 107) were randomized to receive either rapamycin 1% (n = 33), rapamycin 0.5% (n = 36) or placebo (n = 38). All treated participants were included in the final analysis. The percentage of participants with a two-grade IGA improvement was greater in the rapamycin 0.5% treatment group (11%) and rapamycin 1% group (9%) than in the placebo group (5%). However, this was not statistically significant [rapamycin 0.5%: odds ratio (OR) 1.71, 95% confidence interval (CI) 0.36–8.18 (P = 0.50); rapamycin 1%: OR 1.68, 95% CI 0.33–8.40 (P = 0.53)]. There was a statistically significant difference in the proportion of participants treated with rapamycin cream that achieved at least a one-grade improvement in IGA [rapamycin 0.5%: 56% (OR 4.73, 95% CI 1.59–14.10; P = 0.005); rapamycin 1%: 61% (OR 5.14, 95% CI 1.70–15.57; P = 0.004); placebo: 24%]. Skin adverse reactions were more common in patients following rapamycin application (64%) vs. placebo (29%). Conclusions Both rapamycin cream formulations (0.5% and 1%) were well tolerated, and either strength could lead to clinical benefit in the treatment of FA.